New Drug for Myocardial Infarction in Syria

Tuesday, February 1, 2011

One of the most important essential pillars adopted by the national companies of pharmaceutical industry is coping with the development in pharmaceutical and medical fields, particularly in chronic diseases field like (Hypertension, Diabetes Mellitus and chronic arthritis,etc...).

New product was launched in the Syrian Medical Market called Prassuclear (the scientific name: Prasugrel) produced by Ibn Al Haytham Pharma. It is considered to be one of the most recent drugs worldwide which has a presence in the International Pharmaceutical Market since two years.

Prassuclear is regarded as a new beginning in the pharmaceutical drugs field that are used as anti - platelets in which it is considered to be one of the latest anti - platelets aggregation third generation drugs worldwide. It is more effective and has no resistance when used by patients in addition to its lower price than Clopidogrel which is now used widely. All these merits distinguish prassuclear from the first and second generation’s drugs.

This worldwide new drug was provided by Ibn Al Haytham pharma in the Syrian pharmaceutical markets according to the high Quality Control system standards , and with an appropriate economic price for the patients especially that taking this kind of drugs may continue for a long period of years.